Conference
NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).
Abstract
5042
Background: PX-866 is an irreversible, pan-isoform inhibitor of Class I PI-3K. Mutations in PIK3CA and loss of PTEN activity lead to activation of AKT signaling; alterations in these genes occur frequently in prostate cancers while activation of the PI-3K/AKT signaling pathway is implicated in prostate cancer progression and treatment resistance. Hence, novel inhibitors of the pathway such as PX-866 are of interest. …
Authors
Hotte SJ; Eisenhauer EA; Joshua AM; Kumar V; Ellard S; Gregg RW; Macfarlane RJ; Winquist E; Torri V; Ruether JD
Volume
31
Pagination
pp. 5042-5042
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.5042
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X